Atlas Trials

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Clinical trial NCT03501368 · COMPLETED

Trial details

NCT number
NCT03501368
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
MelanomaUnresectable MelanomaAdvanced Melanoma
Start date
2018-06-27
Primary completion
2022-10-28
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.